Sage Journals: Discover world-class research

Abstract

We determined whether positive ANA was related to response to rIFNû-1a in 62 relapsing-remitting MS patients. According to the presence of antinuclear antibodies (ANA) at baseline and during the first 6 months of treatment, patients were sorted in different groups. The clinical and MRI outcome during short-term (6 months) and long-term (24 months) treatment period was not statistically different between the groups. Therefore, the response to IFNb-1a seems not to be influenced by ANA occurrence either before or during treatment. When the analysis was extended to other autoantibodies (i.e. antithyroid, anticardiolipin) similar results were obtained.

Keywords

multiple sclerosis antinuclear antibodies autoantibodies interferon beta-1a therapeutical response disease activity

Get full access to this article

View all access options for this article.

References

Collard RC , Koehler RMP , Mattson DH. (1997) Frequency and significance of antinuclear antibodies in multiple sclerosis . Neurology 49: 857-861 .

Spadaro M et al. (1999) Autoimmunity in multiple sclerosis: a study of a wide spectrum of autoantibodies . Multiple Sclerosis 5: 121-125 .

Pozzilli C , Bastianello S , Gasperini C , Salvetti M. (1998) Antinuclear antibodies and MRI activity in multiple sclerosis . Neurology 51: 650-650 (Letter).

Becker KG et al. (1997) Analysis of a sequenced cDNA library from multiple sclerosis lesions . J Neuroimmunol 77: 27-38 .

Hartung HP et al. (1995) Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging . Ann Neurol 38: 186-193 .

Pozzilli C , Koudriavtseva T. (1997) Interferon beta 1a. In: Clinical neurology: Multiple Sclerosis. Miller DH (ed). Vol 6, num 3, pp 481-493. Baillière Tindall .

Wicks DAG et al. Volume measurement of multiple sclerosis lesions with magnetic resonance images . Neuroradiology 34: 475-479 .

Durelli L et al. (1999) Autoimmune events during interferon beta-1b treatment for multiple sclerosis . J Neurol Sci 162: 74-83 .

Colosimo C et al. (1997) No increase of serum auto-antibodies during therapy with recombinant human interferon-b-1a in relapsing remitting multiple sclerosis . Acta Neurol Scand 96: 372-374 .

10.

Noda K et al. (1996) Induction of antinuclear antibodies after interferon therapy in patients with type-C chronic hepatitis: its relation to the efficacy of therapy . Scand J Gastroenterol 31: 716-722 .

Antinuclear antibodies and response to IFNβ-1a therapy in relapsing-remitting multiple sclerosis

Abstract

Keywords

Get full access to this article

References